Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study

Rose A Gubitosi-Klug, Barbara H Braffett, Neil H White, Robert S Sherwin, F John Service, John M Lachin, William V Tamborlane, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Rose A Gubitosi-Klug, Barbara H Braffett, Neil H White, Robert S Sherwin, F John Service, John M Lachin, William V Tamborlane, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group

Abstract

Objective: During the Diabetes Control and Complications Trial (DCCT), intensive diabetes therapy achieving a mean HbA1c of ∼7% was associated with a threefold increase in the rate of severe hypoglycemia (defined as requiring assistance) compared with conventional diabetes therapy with a mean HbA1c of 9% (61.2 vs. 18.7 per 100 patient-years). After ∼30 years of follow-up, we investigated the rates of severe hypoglycemia in the DCCT/Epidemiology of Diabetes Inverventions and Complications (EDIC) cohort.

Research design and methods: Rates of severe hypoglycemia were reported quarterly during DCCT and annually during EDIC (i.e., patient recall of episodes in the preceding 3 months). Risk factors influencing the rate of severe hypoglycemia over time were investigated.

Results: One-half of the DCCT/EDIC cohort reported episodes of severe hypoglycemia. During EDIC, rates of severe hypoglycemia fell in the former DCCT intensive treatment group but rose in the former conventional treatment group, resulting in similar rates (36.6 vs. 40.8 episodes per 100 patient-years, respectively) with a relative risk of 1.12 (95% CI 0.91-1.37). A preceding episode of severe hypoglycemia was the most powerful predictor of subsequent episodes. Entry into the DCCT study as an adolescent was associated with an increased risk of severe hypoglycemia, whereas insulin pump use was associated with a lower risk. Severe hypoglycemia rates increased with lower HbA1c similarly among participants in both treatment groups.

Conclusions: Rates of severe hypoglycemia have equilibrated over time between the two DCCT/EDIC treatment groups in association with advancing duration of diabetes and similar HbA1c levels. Severe hypoglycemia persists and remains a challenge for patients with type 1 diabetes across their life span.

Trial registration: ClinicalTrials.gov NCT00360815 NCT00360893.

© 2017 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Spline-smoothed estimates of SH per 100 patient-years by calendar time during DCCT (left) and EDIC (right). Solid lines represent rates for the intensive treatment group; dashed lines represent rates for the conventional treatment group.
Figure 2
Figure 2
Risk of any SH (first episode) as a function of the HbA1c values for the intensive treatment group (monthly during DCCT and annually during EDIC) (A) and conventional treatment group (quarterly during DCCT and annually during EDIC) (B). The regression line and its 95% confidence band are provided by the simple exponential Poisson models presented in Supplementary Table 2. Bold lines represent the EDIC period; light lines represent the DCCT period.

References

    1. Nathan DM, Genuth S, Lachin J, et al. .; Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159–2167
    1. Aiello LP; DCCT/EDIC Research Group . Diabetic retinopathy and other ocular findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:17–23
    1. de Boer IH; DCCT/EDIC Research Group . Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:24–30
    1. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group . Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:39–43
    1. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group . Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:31–38
    1. Orchard TJ, Nathan DM, Zinman B, et al. .; Writing Group for the DCCT/EDIC Research Group . Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45–53
    1. The Diabetes Control and Complications Trial Research Group Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286
    1. Tamborlane WV. Severe hypoglycemia in youth with T1DM: going, going … but not yet gone. Pediatr Diabetes 2011;12:1–3
    1. Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188–2195
    1. Miller KM, Foster NC, Beck RW, et al. .; T1D Exchange Clinic Network . Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971–978
    1. Weinstock RS, Xing D, Maahs DM, et al. .; T1D Exchange Clinic Network . Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2013;98:3411–3419
    1. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111
    1. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26:1079–1087
    1. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774
    1. Bergenstal RM, Tamborlane WV, Ahmann A, et al. .; STAR 3 Study Group . Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311–320
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care 2010;33:17–22
    1. McCulloch PNJ. Generalized Linear Models. 2nd ed New York, Chapman and Idall, 1989
    1. Lee E. Statistical Methods for Survival Data Analysis. Belmont, CA, Lifetime Learning Publications, 1980
    1. Lachin JM. Biostatistical Methods: The Assessment of Relative Risks. 2nd ed. New York, John Wiley and Sons, 2011
    1. Little SA, Leelarathna L, Walkinshaw E, et al. . Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114–2122
    1. Pop-Busui R, Low PA, Waberski BH, et al. .; DCCT/EDIC Research Group . Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009;119:2886–2893
    1. Keenan HA, Sun JK, Levine J, et al. . Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846–2853
    1. McGee P, Steffes M, Nowicki M, et al. .; DCCT/EDIC Research Group . Insulin secretion measured by stimulated C-peptide in long-established type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort: a pilot study. Diabet Med 2014;31:1264–1268
    1. Dagogo-Jack S. Philip E. Cryer, MD: seminal contributions to the understanding of hypoglycemia and glucose counterregulation and the discovery of HAAF (Cryer Syndrome). Diabetes Care 2015;38:2193–2199
    1. Jones TW, Porter P, Sherwin RS, et al. . Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998;338:1657–1662
    1. Tamborlane, WV. Triple jeopardy: nocturnal hypoglycemia after exercise in the young with diabetes. J Clin Endocrinol Metab 92:815–816

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi